Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-27 @ 11:22 PM
Study NCT ID:
NCT04579133
Status:
TERMINATED
Last Update Posted:
2021-06-16
First Post:
2020-10-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Sponsor:
Latin American Cooperative Oncology Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-03-01
Start Date Type:
ACTUAL
Primary Completion Date:
2021-03-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-03-01
Completion Date Type:
ACTUAL
First Submit Date:
2020-10-01
First Submit QC Date:
None
Study First Post Date:
2020-10-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-06-14
Last Update Post Date:
2021-06-16
Last Update Post Date Type:
ACTUAL